Geode Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-439,736
| Closed | -$972K | – | 4819 |
|
|
2023
Q2 | $972K | Sell |
439,736
-27,059
| -6% | -$56.1K | ﹤0.01% | 3370 |
|
|
2023
Q1 | $1.19M | Buy |
466,795
+2,358
| +0.5% | +$4.66K | ﹤0.01% | 3264 |
|
|
2022
Q4 | $868K | Buy |
464,437
+22,502
| +5% | +$56.1K | ﹤0.01% | 3413 |
|
|
2022
Q3 | $1.14M | Buy |
441,935
+5,616
| +1% | +$14K | ﹤0.01% | 3330 |
|
|
2022
Q2 | $842K | Sell |
436,319
-369,794
| -46% | -$807K | ﹤0.01% | 3501 |
|
|
2022
Q1 | $2.39M | Buy |
806,113
+45,297
| +6% | +$170K | ﹤0.01% | 3170 |
|
|
2021
Q4 | $3.42M | Buy |
760,816
+63,195
| +9% | +$300K | ﹤0.01% | 3101 |
|
|
2021
Q3 | $3.39M | Sell |
697,621
-26,786
| -4% | -$148K | ﹤0.01% | 3134 |
|
|
2021
Q2 | $4.94M | Buy |
724,407
+29,392
| +4% | +$238K | ﹤0.01% | 2918 |
|
|
2021
Q1 | $4.91M | Buy |
695,015
+60,355
| +10% | +$435K | ﹤0.01% | 2797 |
|
|
2020
Q4 | $3.97M | Buy |
634,660
+44,013
| +7% | +$259K | ﹤0.01% | 2718 |
|
|
2020
Q3 | $3.19M | Buy |
590,647
+4,540
| +0.8% | +$22.5K | ﹤0.01% | 2636 |
|
|
2020
Q2 | $3.06M | Buy |
586,107
+12,709
| +2% | +$56.5K | ﹤0.01% | 2601 |
|
|
2020
Q1 | $1.81M | Buy |
573,398
+98,169
| +21% | +$362K | ﹤0.01% | 2722 |
|
|
2019
Q4 | $1.91M | Buy |
475,229
+68,716
| +17% | +$238K | ﹤0.01% | 3027 |
|
|
2019
Q3 | $1.76M | Buy |
406,513
+13,491
| +3% | +$53.9K | ﹤0.01% | 3011 |
|
|
2019
Q2 | $1.57M | Buy |
393,022
+53,530
| +16% | +$255K | ﹤0.01% | 3078 |
|
|
2019
Q1 | $1.82M | Buy |
339,492
+30,719
| +10% | +$198K | ﹤0.01% | 2910 |
|
|
2018
Q4 | $1.58M | Buy |
308,773
+6,811
| +2% | +$51.7K | ﹤0.01% | 2898 |
|
|
2018
Q3 | $2.93M | Buy |
301,962
+15,902
| +6% | +$160K | ﹤0.01% | 2674 |
|
|
2018
Q2 | $2.92M | Buy |
286,060
+27,095
| +10% | +$307K | ﹤0.01% | 2632 |
|
|
2018
Q1 | $3.37M | Buy |
258,965
+58,183
| +29% | +$866K | ﹤0.01% | 2486 |
|
|
2017
Q4 | $3.59M | Buy |
200,782
+5,151
| +3% | +$107K | ﹤0.01% | 2414 |
|
|
2017
Q3 | $4.91M | Buy |
195,631
+6,184
| +3% | +$144K | ﹤0.01% | 2219 |
|
|
2017
Q2 | $4.57M | Buy |
189,447
+40,485
| +27% | +$895K | ﹤0.01% | 2205 |
|
|
2017
Q1 | $2.87M | Buy |
148,962
+14,392
| +11% | +$227K | ﹤0.01% | 2451 |
|
|
2016
Q4 | $2.07M | Buy |
134,570
+13,931
| +12% | +$181K | ﹤0.01% | 2606 |
|
|
2016
Q3 | $1.57M | Buy |
120,639
+66,828
| +124% | +$886K | ﹤0.01% | 2700 |
|
|
2016
Q2 | $748K | Buy |
53,811
+2,868
| +6% | +$42.2K | ﹤0.01% | 3035 |
|
|
2016
Q1 | $772 | Buy |
50,943
+2,289
| +5% | +$35K | ﹤0.01% | 3019 |
|
|
2015
Q4 | $922K | Buy |
48,654
+1,013
| +2% | +$19.3K | ﹤0.01% | 2949 |
|
|
2015
Q3 | $905K | Buy |
47,641
+2,649
| +6% | +$66K | ﹤0.01% | 2928 |
|
|
2015
Q2 | $1.16M | Buy |
44,992
+34,420
| +326% | +$977K | ﹤0.01% | 2823 |
|
|
2015
Q1 | $330K | Buy |
10,572
+713
| +7% | +$20.5K | ﹤0.01% | 3382 |
|
|
2014
Q4 | $380K | Buy |
9,859
+6,606
| +203% | +$158K | ﹤0.01% | 3306 |
|
|
2014
Q3 | $79K | Hold |
3,253
| – | – | ﹤0.01% | 3789 |
|
|
2014
Q2 | $77K | Sell |
3,253
-365
| -10% | -$11.9K | ﹤0.01% | 3733 |
|
|
2014
Q1 | $133K | Buy |
3,618
+14
| +0.4% | +$553 | ﹤0.01% | 3607 |
|
|
2013
Q4 | $145K | Buy |
3,604
+36
| +1% | +$1.53K | ﹤0.01% | 3515 |
|
|
2013
Q3 | $136K | Buy |
3,568
+267
| +8% | +$9.56K | ﹤0.01% | 3435 |
|
|
2013
Q2 | $120K | Buy |
+3,301
| New | +$141K | ﹤0.01% | 3385 |
|
Geode Capital Management's PRTK Position: Q3 2023 in Review
Geode Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 439,736 shares — an estimated $972K sold.
Geode Capital Management first reported a position in PRTK in Q2 2013 and held it in 41 quarters. The position peaked at $4.94M in Q2 2021. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- Geode Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Geode Capital Management sold 439,736 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $972K.
- Geode Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 41 quarters.
- Geode Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $4.94M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on Geode Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.